See more : Whispir Limited (WHSPF) Income Statement Analysis – Financial Results
Complete financial analysis of ICU Medical, Inc. (ICUI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ICU Medical, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- NewAmsterdam Pharma Company N.V. (NAMSW) Income Statement Analysis – Financial Results
- Mydecine Innovations Group Inc. (MYCOF) Income Statement Analysis – Financial Results
- Metro Brands Limited (METROBRAND.BO) Income Statement Analysis – Financial Results
- DataWalk S.A. (DAT.WA) Income Statement Analysis – Financial Results
- Jupiter Wagons Limited (JWL.NS) Income Statement Analysis – Financial Results
ICU Medical, Inc. (ICUI)
About ICU Medical, Inc.
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.26B | 2.28B | 1.32B | 1.27B | 1.27B | 1.40B | 1.29B | 379.37M | 341.67M | 309.26M | 313.72M | 316.87M | 302.20M | 284.58M | 231.51M | 204.73M | 188.14M | 201.61M | 157.53M | 75.55M | 107.35M | 87.81M | 69.06M | 56.19M | 47.00M | 39.80M | 30.40M | 24.60M | 21.30M | 16.50M | 11.40M | 10.20M | 7.50M |
| Cost of Revenue | 1.52B | 1.58B | 824.82M | 809.51M | 794.34M | 830.01M | 866.52M | 177.97M | 160.87M | 157.86M | 158.98M | 160.36M | 159.84M | 153.99M | 122.70M | 114.91M | 109.90M | 120.93M | 88.13M | 39.85M | 48.44M | 36.46M | 28.93M | 19.18M | 16.00M | 14.30M | 10.70M | 8.40M | 8.50M | 7.70M | 3.90M | 3.00M | 2.20M |
| Gross Profit | 739.87M | 697.76M | 491.49M | 461.50M | 471.86M | 570.03M | 426.10M | 201.40M | 180.80M | 151.40M | 154.73M | 156.51M | 142.35M | 130.59M | 108.82M | 89.82M | 78.24M | 80.68M | 69.40M | 35.70M | 58.91M | 51.34M | 40.12M | 37.02M | 31.00M | 25.50M | 19.70M | 16.20M | 12.80M | 8.80M | 7.50M | 7.20M | 5.30M |
| Gross Profit Ratio | 32.75% | 30.60% | 37.34% | 36.31% | 37.27% | 40.72% | 32.96% | 53.09% | 52.92% | 48.96% | 49.32% | 49.39% | 47.11% | 45.89% | 47.00% | 43.87% | 41.59% | 40.02% | 44.06% | 47.25% | 54.87% | 58.47% | 58.10% | 65.88% | 65.96% | 64.07% | 64.80% | 65.85% | 60.09% | 53.33% | 65.79% | 70.59% | 70.67% |
| Research & Development | 85.34M | 92.98M | 47.50M | 42.95M | 48.61M | 52.87M | 51.25M | 12.96M | 15.71M | 18.33M | 12.41M | 10.63M | 8.59M | 4.68M | 2.65M | 4.82M | 8.11M | 7.66M | 4.82M | 3.38M | 1.76M | 1.47M | 1.19M | 1.48M | 1.20M | 1.00M | 1.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 276.88M | 328.15M | 303.95M | 89.43M | 1.80M | 88.94M | 90.38M | 84.60M | 85.29M | 76.64M | 68.21M | 53.61M | 45.48M | 44.25M | 36.99M | 26.41M | 23.03M | 19.87M | 16.82M | 14.30M | 12.50M | 12.10M | 8.50M | 8.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 100.00K | 600.00K | 200.00K | 100.00K | 81.42M | 100.00K | 300.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 606.69M | 608.35M | 302.58M | 283.95M | 276.98M | 328.15M | 303.95M | 89.43M | 83.22M | 88.94M | 90.38M | 84.60M | 85.29M | 76.64M | 68.21M | 53.61M | 45.48M | 44.25M | 36.99M | 26.41M | 23.03M | 19.87M | 16.82M | 14.30M | 12.50M | 12.10M | 8.50M | 8.20M | 5.60M | 3.90M | 2.80M | 2.30M | 1.20M |
| Other Expenses | 25.01M | -5.14M | 127.00K | -975.00K | 5.74M | 1.47M | -2.48M | 767.00K | 1.13M | 755.00K | 765.00K | 563.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.61M | 3.90M | 2.40M | 2.10M | 2.00M | 1.80M | 1.10M | 500.00K | 200.00K | 100.00K |
| Operating Expenses | 717.05M | 701.33M | 350.21M | 325.93M | 331.33M | 381.01M | 355.21M | 102.38M | 98.93M | 107.27M | 102.78M | 95.23M | 93.88M | 81.31M | 70.85M | 58.43M | 53.60M | 49.81M | 41.81M | 29.79M | 24.79M | 21.34M | 18.00M | 20.39M | 17.60M | 15.50M | 11.90M | 10.20M | 7.40M | 5.00M | 3.30M | 2.50M | 1.30M |
| Cost & Expenses | 2.24B | 2.28B | 1.18B | 1.14B | 1.13B | 1.21B | 1.22B | 280.36M | 259.80M | 265.13M | 261.77M | 255.59M | 253.72M | 235.30M | 193.55M | 173.34M | 163.49M | 170.74M | 129.94M | 69.64M | 73.23M | 57.81M | 46.94M | 39.57M | 33.60M | 29.80M | 22.60M | 18.60M | 15.90M | 12.70M | 7.20M | 5.50M | 3.50M |
| Interest Income | 7.51M | 4.43M | 2.80M | 3.70M | 6.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 102.73M | 66.38M | 858.00K | 1.75M | 549.00K | 709.00K | 2.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 228.77M | 258.80M | 99.29M | 94.85M | 85.21M | 74.74M | 66.57M | 19.05M | 18.07M | 19.45M | 19.51M | 19.00M | 18.29M | 17.35M | 15.67M | 14.22M | 11.80M | 11.23M | 9.70M | 8.60M | 7.36M | 5.29M | 5.03M | 4.61M | 3.90M | 2.40M | 2.10M | 2.00M | 1.80M | 1.10M | 500.00K | 200.00K | 100.00K |
| EBITDA | 253.20M | 191.55M | 223.46M | 194.09M | 200.47M | 271.89M | 205.54M | 118.07M | 99.94M | 63.58M | 72.83M | 80.28M | 84.72M | 65.00M | 52.46M | 40.91M | 27.75M | 35.55M | 37.29M | 5.91M | 41.49M | 35.29M | 27.15M | 21.23M | 17.30M | 12.40M | 9.90M | 8.00M | 7.20M | 4.90M | 4.70M | 4.90M | 4.10M |
| EBITDA Ratio | 11.21% | 9.93% | 10.79% | 10.75% | 11.72% | 13.61% | 5.29% | 34.98% | 33.14% | 22.20% | 22.78% | 25.33% | 16.16% | 23.37% | 22.66% | 19.98% | 14.75% | 17.63% | 21.95% | 17.12% | 37.60% | 38.56% | 36.44% | 34.06% | 33.83% | 27.64% | 28.29% | 27.24% | 30.52% | 26.06% | 36.84% | 46.08% | 92.00% |
| Operating Income | 22.83M | -8.70M | 52.38M | 41.81M | 63.22M | 21.61M | -15.08M | 82.94M | 68.57M | 39.04M | 51.95M | 61.28M | 65.22M | 49.28M | 37.97M | 31.38M | 24.65M | 30.87M | 27.60M | 5.91M | 34.12M | 30.00M | 22.12M | 16.62M | 13.40M | 10.00M | 7.80M | 6.00M | 5.40M | 3.80M | 4.20M | 4.70M | 4.00M |
| Operating Income Ratio | 1.01% | -0.38% | 3.98% | 3.29% | 4.99% | 1.54% | -1.17% | 21.86% | 20.07% | 12.62% | 16.56% | 19.34% | 21.58% | 17.32% | 16.40% | 15.33% | 13.10% | 15.31% | 17.52% | 7.83% | 31.79% | 34.17% | 32.03% | 29.58% | 28.51% | 25.13% | 25.66% | 24.39% | 25.35% | 23.03% | 36.84% | 46.08% | 53.33% |
| Total Other Income/Expenses | -101.12M | -71.51M | -59.00K | -668.00K | 7.35M | -7.38M | 64.58M | 2.22M | 1.13M | 755.00K | 765.00K | 563.00K | 1.20M | 129.00K | 1.18M | 4.70M | 8.70M | 4.46M | 2.72M | 1.58M | 1.12M | 1.43M | 1.99M | 2.10M | 1.40M | 1.40M | 1.40M | 1.20M | 800.00K | 600.00K | -100.00K | 100.00K | -2.90M |
| Income Before Tax | -78.30M | -114.41M | 123.19M | 97.49M | 114.71M | 22.37M | 51.28M | 85.16M | 69.70M | 39.79M | 52.71M | 61.84M | 66.42M | 49.41M | 39.15M | 36.08M | 33.35M | 35.34M | 30.32M | 7.49M | 35.25M | 31.43M | 24.11M | 18.72M | 14.80M | 11.40M | 9.20M | 7.20M | 6.20M | 4.40M | 4.10M | 4.80M | 1.10M |
| Income Before Tax Ratio | -3.47% | -5.02% | 9.36% | 7.67% | 9.06% | 1.60% | 3.97% | 22.45% | 20.40% | 12.87% | 16.80% | 19.52% | 21.98% | 17.36% | 16.91% | 17.62% | 17.72% | 17.53% | 19.24% | 9.92% | 32.83% | 35.80% | 34.91% | 33.31% | 31.49% | 28.64% | 30.26% | 29.27% | 29.11% | 26.67% | 35.96% | 47.06% | 14.67% |
| Income Tax Expense | -48.64M | -40.12M | 20.05M | 10.62M | 13.67M | -6.42M | -17.36M | 22.08M | 24.71M | 13.46M | 12.30M | 20.56M | 21.75M | 18.48M | 12.59M | 11.78M | 10.34M | 10.24M | 10.46M | -109.00K | 12.95M | 11.75M | 8.72M | 6.93M | 5.40M | 4.20M | 3.50M | 2.50M | 2.00M | 1.50M | 1.10M | 800.00K | 200.00K |
| Net Income | -29.66M | -74.29M | 103.14M | 86.87M | 101.04M | 28.79M | 68.64M | 63.08M | 44.99M | 26.34M | 40.42M | 41.28M | 44.67M | 30.93M | 26.56M | 24.30M | 23.08M | 25.66M | 20.27M | 5.00M | 22.30M | 19.68M | 15.39M | 11.79M | 9.40M | 7.20M | 5.70M | 4.70M | 4.20M | 2.90M | 3.30M | 4.90M | 3.00M |
| Net Income Ratio | -1.31% | -3.26% | 7.84% | 6.83% | 7.98% | 2.06% | 5.31% | 16.63% | 13.17% | 8.52% | 12.88% | 13.03% | 14.78% | 10.87% | 11.47% | 11.87% | 12.27% | 12.73% | 12.87% | 6.62% | 20.77% | 22.42% | 22.28% | 20.98% | 20.00% | 18.09% | 18.75% | 19.11% | 19.72% | 17.58% | 28.95% | 48.04% | 40.00% |
| EPS | -1.23 | -3.11 | 4.86 | 4.16 | 4.90 | 1.33 | 3.50 | 3.90 | 2.84 | 1.72 | 2.75 | 2.90 | 3.23 | 2.20 | 1.80 | 1.72 | 1.62 | 1.78 | 1.47 | 0.37 | 1.62 | 1.43 | 1.20 | 0.95 | 0.77 | 0.60 | 0.47 | 0.36 | 0.35 | 0.27 | 0.32 | 0.47 | 0.36 |
| EPS Diluted | -1.23 | -3.11 | 4.74 | 4.02 | 4.69 | 1.33 | 3.29 | 3.66 | 2.73 | 1.68 | 2.65 | 2.80 | 3.15 | 2.16 | 1.77 | 1.67 | 1.51 | 1.64 | 1.35 | 0.33 | 1.48 | 1.28 | 1.06 | 0.87 | 0.72 | 0.57 | 0.47 | 0.36 | 0.35 | 0.27 | 0.31 | 0.47 | 0.36 |
| Weighted Avg Shares Out | 24.09M | 23.87M | 21.21M | 20.91M | 20.63M | 21.60M | 19.61M | 16.17M | 15.85M | 15.28M | 14.69M | 14.22M | 13.84M | 13.61M | 14.72M | 14.14M | 14.28M | 14.41M | 13.81M | 13.69M | 13.75M | 13.79M | 12.84M | 12.50M | 12.23M | 11.98M | 11.92M | 13.26M | 11.88M | 10.60M | 10.31M | 10.49M | 8.33M |
| Weighted Avg Shares Out (Dil) | 24.09M | 23.87M | 21.78M | 21.59M | 21.55M | 21.60M | 20.86M | 17.25M | 16.50M | 15.65M | 15.27M | 14.73M | 14.16M | 13.86M | 14.98M | 14.56M | 15.27M | 15.60M | 15.04M | 14.96M | 15.05M | 15.35M | 14.45M | 13.59M | 13.04M | 12.63M | 12.04M | 13.26M | 12.11M | 10.87M | 10.76M | 10.49M | 8.33M |
ICU Medical Pulls Amino Acid IV Products After Foreign Substances Found In Batch
Why ICU Medical Stock Is Jumping Today
ICUI Stock: What Is the Huge News Sending ICU Medical Soaring 35% Today
ICUI Stock: Over 35% Increase Explanation
ICU Medical, Inc. (ICUI) CEO Vivek Jain on ICU Medical's Smiths Medical Division Acquisition (Transcript)
ICU Medical, Inc. to acquire Smiths Medical division from Smiths Group plc for $2.35 billion in cash and stock plus the assumption of certain liabilities and a stock price performance-based earn-out
ICU Medical Issues a Voluntary Nationwide Recall of Aminosyn II 15%, An Amino Acid Injection, Sulfite Free IV Solution Due to the Presence of Particulate Matter
ICU Medical, Inc.'s (ICUI) CEO Vivek Jain on Q2 2021 Results - Earnings Call Transcript
ICU Medical (ICUI) Q2 Earnings and Revenues Beat Estimates
ICU Medical, Inc. Announces Second Quarter 2021 Results
Source: https://incomestatements.info
Category: Stock Reports